329 related articles for article (PubMed ID: 33535841)
1. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications.
Godman B; Hill A; Simoens S; Selke G; Selke Krulichová I; Zampirolli Dias C; Martin AP; Oortwijn W; Timoney A; Gustafsson LL; Voncina L; Kwon HY; Gulbinovic J; Gotham D; Wale J; Cristina Da Silva W; Bochenek T; Allocati E; Kurdi A; Ogunleye OO; Meyer JC; Hoxha I; Malaj A; Hierländer C; Sauermann R; Hamelinck W; Petrova G; Laius O; Langner I; Yfantopoulos J; Joppi R; Jakupi A; Greiciute-Kuprijanov I; Vella Bonanno P; Piepenbrink JH; de Valk V; Wladysiuk M; Marković-Peković V; Mardare I; Fürst J; Tomek D; Obach Cortadellas M; Zara C; Pontes C; McTaggart S; Laba TL; Melien Ø; Wong-Rieger D; Bae S; Hill R
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):527-540. PubMed ID: 33535841
[No Abstract] [Full Text] [Related]
2. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
3. Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.
Godman B; Bucsics A; Vella Bonanno P; Oortwijn W; Rothe CC; Ferrario A; Bosselli S; Hill A; Martin AP; Simoens S; Kurdi A; Gad M; Gulbinovič J; Timoney A; Bochenek T; Salem A; Hoxha I; Sauermann R; Massele A; Guerra AA; Petrova G; Mitkova Z; Achniotou G; Laius O; Sermet C; Selke G; Kourafalos V; Yfantopoulos J; Magnusson E; Joppi R; Oluka M; Kwon HY; Jakupi A; Kalemeera F; Fadare JO; Melien O; Pomorski M; Wladysiuk M; Marković-Peković V; Mardare I; Meshkov D; Novakovic T; Fürst J; Tomek D; Zara C; Diogene E; Meyer JC; Malmström R; Wettermark B; Matsebula Z; Campbell S; Haycox A
Front Public Health; 2018; 6():328. PubMed ID: 30568938
[No Abstract] [Full Text] [Related]
4. Assessing the pricing and benefits of oncology products: an update.
Petrou P
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):335-342. PubMed ID: 33950772
[No Abstract] [Full Text] [Related]
5. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
[TBL] [Abstract][Full Text] [Related]
6. Medicine price transparency and confidential managed-entry agreements in Europe: findings from the EURIPID survey.
Russo P; Carletto A; Németh G; Habl C
Health Policy; 2021 Sep; 125(9):1140-1145. PubMed ID: 34253396
[TBL] [Abstract][Full Text] [Related]
7. Price comparison of high-cost originator medicines in European countries.
Vogler S; Zimmermann N; Babar ZU
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
[TBL] [Abstract][Full Text] [Related]
8. Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe.
Vončina L; Strbad T; Fürst J; Dimitrova M; Kamusheva M; Vila M; Mardare I; Hristova K; Harsanyi A; Atanasijević D; Banović I; Bobinac A
Appl Health Econ Health Policy; 2021 Nov; 19(6):915-927. PubMed ID: 34553334
[TBL] [Abstract][Full Text] [Related]
9. New pricing models for generic medicines to ensure long-term sustainable competition in Europe.
Francois C; Gawlik G; Mestre-Ferrandiz J; Pana A; Perelman J; Yfantopoulos J; Simoens S
Front Pharmacol; 2023; 14():1200641. PubMed ID: 37876734
[No Abstract] [Full Text] [Related]
10. Drug pricing and value in oncology.
Danzon PM; Taylor E
Oncologist; 2010; 15 Suppl 1():24-31. PubMed ID: 20237214
[TBL] [Abstract][Full Text] [Related]
11. Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience.
Dunlop WCN; Staufer A; Levy P; Edwards GJ
Health Policy; 2018 May; 122(5):528-532. PubMed ID: 29567205
[TBL] [Abstract][Full Text] [Related]
12. Tackling reimbursement challenges to fair access to medicines - introduction to the topic.
Tachkov K; Savova A; Manova M; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(6):597-606. PubMed ID: 37055731
[TBL] [Abstract][Full Text] [Related]
13. Indication-specific pricing of pharmaceuticals in the US healthcare system.
Pearson SD; Dreitlein WB; Henshall C; Towse A
J Comp Eff Res; 2017 Jul; 6(5):397-404. PubMed ID: 28699779
[TBL] [Abstract][Full Text] [Related]
14. Managed Entry Agreements: Policy Analysis From the European Perspective.
Dabbous M; Chachoua L; Caban A; Toumi M
Value Health; 2020 Apr; 23(4):425-433. PubMed ID: 32327159
[TBL] [Abstract][Full Text] [Related]
15. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
[No Abstract] [Full Text] [Related]
16. Accelerating patient access to oncology medicines with multiple indications in Europe.
Lawlor R; Wilsdon T; Darquennes E; Hemelsoet D; Huismans J; Normand R; Roediger A
J Mark Access Health Policy; 2021; 9(1):1964791. PubMed ID: 34436506
[No Abstract] [Full Text] [Related]
17. European perspective on the costs and cost-effectiveness of cancer therapies.
Drummond MF; Mason AR
J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe.
Vokinger KN; Hwang TJ; Daniore P; Lee CC; Tibau A; Grischott T; Rosemann TJ; Kesselheim AS
JAMA Oncol; 2021 Sep; 7(9):e212026. PubMed ID: 34196656
[TBL] [Abstract][Full Text] [Related]
19. Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis.
Son KB
Global Health; 2020 Oct; 16(1):98. PubMed ID: 33054820
[TBL] [Abstract][Full Text] [Related]
20. Talkin' About a Resolution: Issues in the Push for Greater Transparency of Medicine Prices.
Shaw B; Mestre-Ferrandiz J
Pharmacoeconomics; 2020 Feb; 38(2):125-134. PubMed ID: 31956967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
